Randomized trial · people

Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetes

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In adults with type 1 diabetes and obesity on automated insulin delivery, adding semaglutide improved time in range and weight over 26 weeks, with the same number of severe lows as placebo.

Kind
Randomized trial
Studied in
People
Number studied
72
Published
2025
Journal
NEJM Evid

What they tested

The team tested whether weekly semaglutide helps adults with type 1 diabetes and obesity who already use an automated insulin delivery system reach blood sugar and weight goals.

How the study was done

A randomized, double-blind, placebo-controlled trial in 72 adults with type 1 diabetes, a body mass index of 30 or higher, and an automated insulin delivery (AID) system, a pump linked to a glucose sensor. For 26 weeks, they got weekly semaglutide up to 1 mg or placebo, a dummy shot.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

To meet the main goal, a person needed more than 70% of the time with glucose between 70 and 180 mg/dl on a continuous glucose monitor (CGM, a wearable sensor), less than 4% of the time below 70 mg/dl, and at least 5% weight loss. 36% of the semaglutide group met every part, compared with 0% on placebo (P<0.001). Compared with placebo, the semaglutide group changed by -0.3 percentage points in glycated hemoglobin (HbA1c, a longer-term average of blood sugar), gained 8.8 percentage points of time in the 70 to 180 mg/dl range, and changed by -8.8 kg in body weight. Each group had two severe low blood sugar events, and there was no diabetic ketoacidosis.

What it doesn’t show

This was a small, 26-week trial, so it can't show longer-term effects or rarer side effects. Everyone used an AID system, so the result may not apply to people with type 1 diabetes on other insulin setups.

The paper

Shah et al. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025.

The compound

More studies on Semaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo